此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

AV-23-001 AVAVA MIRIA 试点研究

2026年11月9日 更新者:AVAVA, Inc.

This non-significant risk study is intended to demonstrate the use of the MIRIA Skin Treatment System can show improvement in dermatologic conditions currently indicated for treatment with a laser (such as, but not limited to, benign pigmented lesions, benign cutaneous lesions, wrinkles, textural irregularities, or scars). The study is also intended to assist in determination of the optimal laser configuration and treatment parameters that most consistently yield results.

研究概览

详细说明

This study is intended to allow clinical evaluation of the feasibility of the MIRIA Skin Treatment System, referred to herein as the SR Skin Rejuvenation Laser, for the treatment of dermatologic conditions currently indicated for treatment with a laser (such as, but not limited to, benign pigmented lesions, benign cutaneous lesions, wrinkles, textural irregularities, or scars). This clinical evaluation is being performed under an investigational protocol to formally collect data for the treatment of different dermatologic conditions.

This prospective, non-randomized, controlled study will include subjects with dermatologic conditions that are currently indicated for treatment with a laser who are willing to have sites exposed to the MIRIA Laser and who agree to comply with the study requirements during the follow-up period, a minimum of 3 months and a maximum of 18 months. Some areas with the dermatologic condition may be left as a control for the treated section. Subjects may also be directed to use some topical cream or lotion for up to 1 month prior to the laser procedure or during the duration of the study, according to the Investigator's standard practice.

研究类型

介入性

注册 (实际的)

10

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • New York
      • Dix Hills、New York、美国、11746
        • Skinfluence Long Island
      • New York、New York、美国、10010
        • Laser and Skin Surgery Center of New York

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Male or female subjects > 18 years of age.

  2. Dermatologic condition currently indicated for laser treatment OR the subject is to be enrolled for assessment of treatment parameters on normal skin.

  3. Willingness to have multiple areas exposed.

  4. Willingness to have digital photographs taken of treatment area(s) and agreement with use of photographs for presentation, educational, or marketing purposes.

  5. Willingness to comply with the following during the study, including the follow-up period:

    1. maintain consistent skin care regimen on treated areas.
    2. Willingness to cover treated areas or have very limited sun exposure and, if requested, use an approved sunscreen of SPF 50 or higher.
    3. refrain from using systemic corticosteroids, according to Investigator discretion.
    4. refrain from using topical corticosteroids, retinoids, or prescription skin-lightening medications on the treated areas, according to Investigator discretion.
    5. refrain from any other procedures in the treatment areas.
  6. Willingness and ability to comply with study instructions and return for required visits.

  7. Subject understands that fees will be collected at the time of treatment ranging from $300 to $3000 per treatment depending upon number of anatomical areas treated. The exact amount will be disclosed and recorded within the consent.

  8. Subject has read and signed a written informed consent form.

  9. Subject lives within 50 miles of study site.

  10. For Males: Willingness to shave facial hair on treatment areas.

    Exclusion Criteria:

  11. Skin pathology or condition that could interfere with evaluation of the study procedure, e.g.,

  12. Systemic treatment prescribed within previous 6 months (e.g., oral medication such as isotretinoin)

  13. Surgical treatment in the target areas within previous 6 months (e.g., laser surgery)

  14. Active vitiligo, psoriasis, or eczema in the treatment area

  15. The timing of use of fillers, neuromodulators and other cosmetic procedures are at the discretion of the investigator.

  16. Topical treatment applied to target areas within the previous 1 month or according to Investigator discretion.

  17. Active suntan and unable or unlikely to refrain from tanning within the follow-up period.

  18. Artificial tanning in the target areas within the previous 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period.

  19. Active localized or systemic infection, or an open wound in area being treated.

  20. Lesions in the treatment areas suspicious for malignancy (skin cancer, melanoma)

  21. History of abnormal wound healing or abnormal scarring (e.g., hypertrophic or keloid)

  22. History of connective tissue disease, such as lupus or scleroderma.

  23. Any use of medication that is known to increase sensitivity to light according to Investigator's discretion (e.g., topicals that produce sensitivity to light may be used in areas other than the target area).

  24. History of gold therapy.

  25. History of disease stimulated by heat, such as recurrent herpes simplex or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.

  26. History of radiation to the treatment area or currently undergoing systemic chemotherapy for the treatment of cancer.

  27. For Female: Pregnancy or lactation, or intent to become pregnant within the study period.

  28. Significant uncontrolled concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension.

  29. History of immunosuppression/immune deficiency disorder or currently using immunosuppressive medications.

  30. Current enrollment in a clinical study of any other unapproved investigational drug or device unless it is a noninvasive dermal study for which the subject is in a follow-up period and has other areas of skin that meet the study criteria or has received an investigational drug or been treated with an investigational device within 30 days prior to entering this study.

  31. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treated Cohort

Experimental: Treatment with the MIRIA Laser 3-4 experimental treatments at 4-6 week intervals. Refine usage of device

The MIRIA Skin Treatment System is a 1550nm-based laser system indicated for use in dermatologic procedures requiring the coagulation of soft tissue, as well as for skin resurfacing procedures.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Global Aesthetic Improvement Scale (GAIS)
大体时间:3 Months

Scale used to compare before and after images of subjects treated. Scores include the following:

  1. - Very Much Improved
  2. - Much Improved
  3. - Improved
  4. - No Change
  5. - Worse
3 Months

次要结果测量

结果测量
措施说明
大体时间
Subject Questionnaire
大体时间:Immediate Post Treatment, 3 Months Post Treatment

Questionnaire that evaluates the subjects impression of the treatment (overall discomfort score, satisfaction with treatment results, notes on treatment sensation).

Immediate Post Treatment, 3 Months Post Treatment
Adverse Event Assessment
大体时间:Immediate Post Treatment, 3 Months Post Treatment

An assessment of side effects and adverse event profile to ensure safety of treatment. Data collected included the event, the duration, the severity, and any other interventions that may occur due to the adverse event.

Immediate Post Treatment, 3 Months Post Treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Hyemin Pomerantz, MD、AVAVA, Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年11月6日

初级完成 (实际的)

2024年7月3日

研究完成 (实际的)

2024年7月3日

研究注册日期

首次提交

2023年12月11日

首先提交符合 QC 标准的

2024年8月13日

首次发布 (实际的)

2024年8月16日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅